Volume 95 Issue 48 | p. 12 | News of The Week
Issue Date: December 4, 2017

AstraZeneca to spin off Shanghai R&D

Move follows reduction in China research footprint by other big drug firms
Department: Business
Keywords: Drug discovery, AstraZeneca, China, Eli Lilly, GSK

Joining other Western drug companies that are scaling back their research commitment in China, AstraZeneca says it will turn its R&D center in Shanghai into a joint venture with a Chinese investor.

. . .

To view the rest of this content, please log in with your ACS ID.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society